Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype

HER2+ breast cancer (BC) is an aggressive subtype genetically and biologically heterogeneous. We evaluate the predictive and prognostic role of HER2 protein/gene expression levels combined with clinico-pathologic features in 154 HER2+ BCs patients who received trastuzumab-based neoadjuvant chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Orrù, Sandra, Pascariello, Emanuele, Pes, Barbara, Rallo, Vincenzo, Barbara, Raffaele, Muntoni, Marta, Notari, Francesca, Fancello, Gianfranco, Mocci, Cristina, Muroni, Maria Rosaria, Cossu-Rocca, Paolo, Angius, Andrea, De Miglio, Maria Rosaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10409859/
https://www.ncbi.nlm.nih.gov/pubmed/37553381
http://dx.doi.org/10.1038/s41598-023-40071-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10409859/
https://www.ncbi.nlm.nih.gov/pubmed/37553381
http://dx.doi.org/10.1038/s41598-023-40071-2

Ejemplares similares